Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency — Stella

Home/Inherited Bone Marrow Failure Syndrome/

View on ClinicalTrials.gov

Recruiting

Back to Inherited Bone Marrow Failure Syndrome trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Phase

Early testing

Sponsor

National Cancer Institute (NCI)

Enrollment target

~75 participants

Started

December 2023

Primary completion

October 2026

Age range

18 Years – 120 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.